DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,894,970 B2 Tomczuk Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,894,970 B2 Tomczuk Et Al US008894970B2 (12) United States Patent (10) Patent No.: US 8,894,970 B2 Tomczuk et al. (45) Date of Patent: Nov. 25, 2014 (54) ARGINASE INHIBITORS AND METHODS OF 546/184, 133, 138, 139, 152; 548/560; USE THEREOF 540/484 See application file for complete search history. (75) Inventors: Bruce Edward Tomczuk, Collegeville, PA (US); Gary Lee Olson, (56) References Cited Mountainside, NJ (US); Richard Scott Pottorf, Belle Mead, NJ (US); Lijuan U.S. PATENT DOCUMENTS Jane Wang, Wildwood, MO (US); Bhask Rao Nall h 4.483,853. A 11/1984 Collins et al. naskara Kao Nalagancnu, 5,792,769 A * 8/1998 Lu et al. ...... 514,252.12 Hillsborough, NJ (US); Yanqun Zhang, 5,891,909 A * 4/1999 Soll et al. ...................... 514/517 East Brunswick, NJ (US) 6,037,356 A * 3/2000 Lu et al. ...... ... 514,349 6,133,315 A * 10/2000 Lu et al. ...... 514/517 6,204.263 B1* 3/2001 Lu et al. ...... 514,235.8 (73) Assignee: Corridor Pharmaceuticals, Inc., 6,225,302 B1* 5/2001 Lu et al. ......... ... 514, 183 Towson, MD (US) 6,235,778 B1* 5/2001 Tomczuk et al. 514/517 6,245,763 B1* 6/2001 Lu et al. ......... ... 514,247 (*) Notice: Subject to any disclaimer, the term of this 6,281.206 B1 : 8/2001 Lu et al. ...... ... 514, 183 patent is extended or adjusted under 35 6,326,492 B1* 12/2001 Wang et al. ..................... 544, 63 6,344,466 B2 * 2/2002 Soll et al. ....... ... 514,331 U.S.C. 154(b) by 356 days. 6,344,484 B1* 2/2002 Tomczuk et al. 514/565 6,344,486 B1* 2/2002 Soll et al. ....... ... 514,620 (21) Appl. No.: 13/191,160 6,350,764 B2* 2/2002 Lu et al. ...... ... 514,349 6,414,020 B2 * 7/2002 Lu et al. ...... 514/517 22) Filed: Jul. 26, 2011 6,417,161 B1* 7/2002 Lu et al. ....................... 514f13.6 (22) File l. A0. 6,472.399 B2 * 10/2002 Lu et al. ...... 514,255.05 6,476,016 B2 * 1 1/2002 Wang et al. .............. 514, 21108 (65) Prior Publication Data 6,514,978 B2 * 2/2003 Lu et al. ................... 514,255.06 6,518,310 B2 * 2/2003 Tomczuk et al. ............. 514,613 US 2012/O17111.6 A1 Jul. 5, 2012 6,521,663 B2 * 2/2003 Panet al. ....... ... 514,518 6,566,379 B1* 5/2003 Lu et al. ...... ... 514,345 6,635,637 B2 * 10/2003 Wang et al. ... ... 514,228.8 Related U.S. Application Data 6,638.931 B1 * 10/2003 Tomczuk et al. ... 514,238.2 6,706,021 B2 * 3/2004 Lu et al. ............. ... 604/244 (60) Provisional application No. 61/428,894, filed on Dec. 6,706,765 B2 * 3/2004 Tomczuk et al. .. ... 514,605 31, 2010, provisional application No. 61/450,804, 6,730,783 B2 * 5/2004 Tomczuk et al. .. ... 544,158 filed on Mar. 9, 2011 7,029,654 B2 * 4/2006 Lu et al. .. 424/91 • - s 7,402.586 B2 * 7/2008 Lu et al. .. ... 514,269 2004/OO57926 A1 3/2004 Ochoa et al. (51) Int. Cl. 2005/0176651 A1 8/2005 Madge et al. A6 IK5I/00 (2006.01) 2007/0185060 A1 8/2007 Wang A6M 36/14 (2006.01) 2010, O189644 A1 7/2010 Christianson et al. A6 IK3I/69 (2006.01) C07F 5/02 (2006.01) FOREIGN PATENT DOCUMENTS A61 K5 I/04 (2006.01) WO WO 2010/085797 T 2010 A61 K 49/00 (2006.01) WO WO 2011, 133653 10, 2011 (52) U.S. Cl. CPC ............... A6 IK3I/69 (2013.01); A61 K5 I/044 OTHER PUBLICATIONS (2013.01); A61K 49/0004 (2013.01); C07F 5/02 (2013.01) Busnel, O... et al., “Synthesis and evaluation of new omega-borono USPC ......... 424/1.69: 424/1.11: 424/1.65: 424/9.1: alpha-amino acids as rat liver arginase inhibitors. Bioorganic & s s Sf Medicinal Chemistry, 2005, 13(7):2373-2379. (58) Field of Classification Search (Continued) CPC ... A61K 51/08: A61 K51/0497; A61K 51/00; A61KAcik 51/04; 5/044. A61K 51/041:Asiks i?olac.A61K 51/044: Acik Primary Examiner DIJones 51/0453: A61K 51/0459; A61K 51/0463: (74) Attorney, Agent, or Firm — Saul Ewing LLP. Kathryn A61K 51/0465, A61K51/0468. A61K51/047. Doyle; Domingos J. Silva A61 K51/06; A61K 51/065; A61K 2123/00; A61K 2121/00; A61K 38/00; A61K 38/005; (57) ABSTRACT A61 K38/02: A61K 38/03: A61K 38/04; Th ion includ inhibi A61K 49/0002: A61K 49/0004: A61K 49/00; e present invention includes arginase enzyme inhibitors, A61K 49/001: A61K 49/0013: A61K 49/0015: compositions comprising these arginase inhibitors, and meth A61K 49/OO17: A61 K 49/OO.19 A61K ods of treating or diagnosing conditions characterized either 49/0021: A61K 49/005: A61 K31 (00: A61 K by abnormally high arginase activity or abnormally low nitric s 31f89: Co7F 5/O2: C07F 5/OO oxide levels in a mammal, comprising administering compo USPC 424/1.11, 1.65, 9.19.2, 9.3, 9.4, 9.5 sitions of the invention to the mammal. 424/9.6, 9.7, 9.8, 1.69: 514/1, 1.1; 530/300: 544/336, 98, 59, 105,349; 546/255, 2 Claims, 13 Drawing Sheets US 8,894,970 B2 Page 2 (56) References Cited N-hydroxy-I-homoarginine from I-glutamate.” ARKIVOC, 2003, 8:180-187. Hey, C., et al., “Inhibition of arginase in rat and rabbit alveolar OTHER PUBLICATIONS macrophages by Nomega-hydroxy-D.L-indospicine, effects on Moali, C., et al., “Recognition of alpha-Amino acids Bearing Various L-arginine utilization by nitric oxide synthase.” British Journal of Pharmacology, 1997, 121(3):395-400. C:NOH Functions by Nitric Oxide Synthase and Arginase Involves Reddy, V.J., et al., “Concise synthesis of omega-borono-alpha-amino Very Different Structural Determinants.” Biochemistry, 2000, acids.” Organic & Biomolecular Chemistry, 2007, 5(6):889-891. 39(38):8208-8218. Colleluori. D., et al., “Classical and Slow-Binding Inhibitors of Collet, S., et al., “Synthesis and evaluation of omega-borono-alpha Human Type II Arginase.” Biochemistry, 2001, 40:9356-93.62. amino acids as active-site probes of arginase and nitric oxide International Search Report for PCT/US2010/022090, mailed Sep. synthases.” J. Chem. Soc., Perkin Trans. 1, 2000, 2:177-182. 14, 2010. Kabasawa, H., et al., “Divergent synthesis of N-hydroxy-I- indospicine, the carbon isostere of N-hydroxy-l-arginine, and * cited by examiner U.S. Patent Nov. 25, 2014 Sheet 1 of 13 US 8,894,970 B2 chnur PhC=NH DCM 2a-C O R = Me, Et, tBu Phe-N sus R Ph 4a-C O Brulls-R R = Me, Et, tBu Ph2C=NH DEA 3a-C CH3CN R = Me, Et, tBu U.S. Patent Nov. 25, 2014 Sheet 2 of 13 US 8,894,970 B2 Fig. 2 B1N1OH 2-butanOne R 85 °C HO N1-a-Nsu1SN HN N-R \ / 7 6 R = Boc, alkyl, aralkyl aryl, heteroary 1)NH 8 Na(OAc)3BH3 N N HO o DCM/TMOF n-N-NsuN 12 R O 10 \ , / H R 9 12, imidazole 1N-R 7 Or 10 E - N-1-Nu 11 U.S. Patent Nov. 25, 2014 Sheet 3 of 13 US 8,894,970 B2 Phsen ork Se:O Ph 21 r (cod) Cl2 N DCMS’ \O--6 C-N D C) N 13 14 U.S. Patent Nov. 25, 2014 Sheet 5 of 13 US 8,894,970 B2 Fig. 6 Ph N Y Y O lk 1. 1 NHC/THF Cbz Rul-kO Ph 2. Cbz-C, DEA 25% TFA/DCM THF -e- ON N Oa N O C)N ; ()N BOC BOC 14 19 () H 20 RNCO DEA RC(=O)Cl DMF DEA DMF 21 22 23 U.S. Patent Nov. 25, 2014 Sheet 6 of 13 US 8,894,970 B2 Fig. 7 Ph. iN -k Ph N-N ul-k 1. Base 2 O 1. Base 2 2. Br(CH2)3OTBS Ph 2. Br11 4C OTBS 24 NH4OHaqueous N k Cbz-Cl Ph Nen -k THF DEA/THF Ph 21 21 OTBS OTBS 25 26 S.BH Cbz-NH O -k HC/THF Cbz NukO O Or TBAF/THF -e- r(COC) Cl2 21 DCMDPPM op OTBS OTBS O 27 28 12, imidazole lk O -k PhP-resin Cbz1 O FSNH DCM -e- R" -e- K2CO3 OH OSBA. op DMF O O 29 3O C bz1 Rul-kO O 1N O 31 U.S. Patent Nov. 25, 2014 Sheet 7 of 13 US 8,894,970 B2 H2N lukO Boc1 NRuk O Sie H (Boc)2O, DIEA O 21 - F - 21 5.5. Cl2 OTBS OTBS DCM 26 32 H -k 1. HC/THF H -k Boc O 2. lg, imidazole -N O R"a ---PhP-resin R" O X B OTBS op DMF O O 33 34 35 U.S. Patent Nov. 25, 2014 Sheet 8 of 13 US 8,894,970 B2 Fig. 9 Phe-N O O lk HF Oyo Citric acid BOC -NH O -k Ph 2. (Boc)2O, DEA 21 THF-> 21 OTBS OTBS 25 32 2. (Boc)2O, DEA Ph THF 21 3. TBSCL DMAR- 21 OTBS OTBS 25 32 U.S. Patent Nov. 25, 2014 Sheet 9 of 13 US 8,894,970 B2 Fig. 10 H 1. He, Pd/C N HCI, THF OH Cbz 2. TFA/DCM 3. PhB(OH)2 1 NHC, ether -e- HOS R R" OSBf O HO 31 H N OH BOC 1.
Load more

Recommended publications
  • Phosphodiesterase (PDE)
    Phosphodiesterase (PDE) Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules. www.MedChemExpress.com 1 Phosphodiesterase (PDE) Inhibitors, Activators & Modulators (+)-Medioresinol Di-O-β-D-glucopyranoside (R)-(-)-Rolipram Cat. No.: HY-N8209 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A (+)-Medioresinol Di-O-β-D-glucopyranoside is a (R)-(-)-Rolipram is the R-enantiomer of Rolipram. lignan glucoside with strong inhibitory activity Rolipram is a selective inhibitor of of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM phosphodiesterase. and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg (R)-DNMDP (S)-(+)-Rolipram Cat. No.: HY-122751 ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (R)-DNMDP is a potent and selective cancer cell (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, AMP(cAMP)-specific phosphodiesterase (PDE) binds PDE3A directly.
    [Show full text]
  • Use of Sildenafil in Patients with Cardiovascular Disease
    Arq Bras Cardiol GuimarãesReview et al volume 73, (nº6), 1999 Sildenafil in patients with cardiovascular disease Use of Sildenafil in Patients with Cardiovascular Disease Armênio Costa Guimarães, Marcus Vinícius Bolívar Malachias, Otávio Rizzi Coelho, Emílio Cesar Zilli, Rafael Leite Luna Introduction of phosphodiesterase inhibitors. The erectile action of sildenafil combines increase in arterial flow with reduction Erectile dysfunction, formerly called impotence, is the in the venous flow of cavernous body of penis. Sildenafil inability of the male to achieve or maintain penile erection and leads to relaxation of smooth muscle of penile arteries and thus engage in coitus1. It is common among patients with trabeculae surrounding the sinusoidal spaces, resulting in cardiovascular diseases or their risk factors. This dysfunc- a greater engorgement of cavernous body. The trabeculae tion occurs mainly among individuals with coronary artery of engorged sinusoidal spaces compress the penile disease, after episodes of acute ischemic syndrome, hyper- venules against the tunica albuginea, reducing venous tensive patients underpharmacologic treatment, and among flow, contributing to maintenance of engorgement of patients with heart failure. In approximately 85% of these ca- cavernous body8. Relaxation of this smooth muscle ses, the fear of a cardiac event during coitus constitutes an results from a decrease in intracellular calcium mediated important factor for erectile dysfunction 2-4. by accumulation of the second messenger, the cyclic Discovery of sildenafil citrate has represented a great de- guanosine monophosphate (cGMP), whose production velopment in the treatment of erectile dysfunction; it may results from activation of guanyl cyclase by nitric oxide benefit, among many others, those patients with cardiovascu- produced by the stimulus of endothelial cells generated lar diseases or with their risk factors 5.
    [Show full text]
  • General Pharmacology
    GENERAL PHARMACOLOGY Winners of “Nobel” prize for their contribution to pharmacology Year Name Contribution 1923 Frederick Banting Discovery of insulin John McLeod 1939 Gerhard Domagk Discovery of antibacterial effects of prontosil 1945 Sir Alexander Fleming Discovery of penicillin & its purification Ernst Boris Chain Sir Howard Walter Florey 1952 Selman Abraham Waksman Discovery of streptomycin 1982 Sir John R.Vane Discovery of prostaglandins 1999 Alfred G.Gilman Discovery of G proteins & their role in signal transduction in cells Martin Rodbell 1999 Arvid Carlson Discovery that dopamine is neurotransmitter in the brain whose depletion leads to symptoms of Parkinson’s disease Drug nomenclature: i. Chemical name ii. Non-proprietary name iii. Proprietary (Brand) name Source of drugs: Natural – plant /animal derivatives Synthetic/semisynthetic Plant Part Drug obtained Pilocarpus microphyllus Leaflets Pilocarpine Atropa belladonna Atropine Datura stramonium Physostigma venenosum dried, ripe seed Physostigmine Ephedra vulgaris Ephedrine Digitalis lanata Digoxin Strychnos toxifera Curare group of drugs Chondrodendron tomentosum Cannabis indica (Marijuana) Various parts are used ∆9Tetrahydrocannabinol (THC) Bhang - the dried leaves Ganja - the dried female inflorescence Charas- is the dried resinous extract from the flowering tops & leaves Papaver somniferum, P album Poppy seed pod/ Capsule Natural opiates such as morphine, codeine, thebaine Cinchona bark Quinine Vinca rosea periwinkle plant Vinca alkaloids Podophyllum peltatum the mayapple
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,333,354 B1 Schudt (45) Date of Patent: Dec
    USOO6333354B1 (12) United States Patent (10) Patent No.: US 6,333,354 B1 Schudt (45) Date of Patent: Dec. 25, 2001 (54) SYNERGISTIC COMBINATION OF PDE Buerke et al.: “Synergistic platelet inhibitory effect of the INHIBITORS AND ADENYLATE CYCLASE phosphodiesterase inhibitor piroximone and iloprost: Pros AGONSTS OR GUANYL CYCLYSE taglandins in the Cardiovascular System, 1992, 37/suppl. AGONSTS (71–77).* (75) Inventor: Christian Schudt, Constance (DE) O'Grady et al. “A chemically stable analot 9-beta methyl carbacyclin with Similar effects to epoprostenol proStacyclin (73) Assignee: Byk Gulden Lomberg Chemische prostaglandin in I-2 in man” Br J Clin Pharmacol, 18(6). Fabrik GmbH, Constance (DE) 1984 (921-934).* (*) Notice: Subject to any disclaimer, the term of this Crutchley et al. “Effects of Prostacyclin Analogs on the patent is extended or adjusted under 35 Synthesis of Tissue Factor, Tumor Necrosis Facotr-alpha U.S.C. 154(b) by 0 days. and Interleukin-1beta in Human Monocytic THP-1 Cells”, J Pharmacol and Experimental Therapeutics, 271 (1). 1994. (21) Appl. No.: 09/367,850 446-451. (22) PCT Filed: Feb. 24, 1998 Crutchley et al. “Prostacyclin Analogues Inhibit Tissue (86) PCT No.: PCT/EP98/O1047 Factor Expression in the Human Monocytic Cell Line THP-1 Via a Cyclic AMP-Dependent Mechanism” Arterio S371 Date: Aug. 27, 1999 scler. Thromb, 12(6), 1992. 664-670.* S 102(e) Date: Aug. 27, 1999 Turner et al., Br. J. Pharmacol., “Pulmonary effects of type V cyclic GMP specific phosphodiesterase inhibition in the (87) PCT Pub. No.: WO98/37894 anaesthetized guinea-pig", (1994), 111, pp.
    [Show full text]
  • Mechanism of Drug-Induced Qt Interval Prolongation
    ABSTRACT Torsades de pointes (TdP) is a polymorphic ventricular tachycardia characterized by a distinctive pattern of undulating QRS complexes that twist around the isoelectric line. TdP is usually self-terminating or can subsequently degenerate into ventricular fibrillation, syncope, and sudden death. TdP has been associated with QT interval prolongation of the electrocardiogram; therefore, the QT interval has come to be recognized as a surrogate marker for the risk of TdP. International guidelines have been developed to harmonize both the preclinical and clinical studies for the evaluation of drug-induced TdP. However, currently preclinical in vitro and in vivo methods as well as biomarkers for proarrhythmias have been imperfect in predicting drug-induced TdP in humans. It is clear that relevant biomarkers together with appropriate models are needed to assess the arrhythmic risk of new chemical entities. The goal of the present dissertation is to create rabbit with myocardial failing heart as an in vivo animal model to predict TdP in humans and to determine mechanism(s) underlying TdP in this model. Electrocardiograms were recorded from bipolar transthoracic leads in 7 conscious healthy rabbits previously trained to rest quietly in slings. The RR and QT relationship, ii QT=2.4RR0.72 (r2=0.79, p < 0.001) was obtained by slowed the heart rate with 2.0 mg/kg zatebradine, and the algorithm for removing effect of heart rate on QT is QTc = QT/(RR)0.72. QTc lengthened significantly in all conscious rabbits given intravenous cisapride, dofetilide or haloperidol (p < 0.05), and QTc did not change with DMSO (vehicle control), propranolol or enalaprilat.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Bath Salts Or Methylenedioxypyrovalerone (MDPV)
    New Highs for the New Millennium Brandon J. Warrick MD Assistant Clinical Professor Wayne State University Disclosures • No financial disclosures • All treatments mentioned in this talk are FDA approved. • Treatment dosing may exceed package insert Objectives • What are “Bath Salts”? • What is “Spice or K2”? • Epidemiology • Were did designer drugs come from? • Were are designer drugs going? What are “Bath Salts”? Testimonials • “I don’t believe in the hype so I ordered some offline and received in roughly a week and a half. It came in a 250mg package that ran me roughly 18 dollars with tax and shipping included. I tried roughly 10mg and absolutely loved it. Immediately after ingestion of the bath salts I felt a rush of energy and even a slight euphoria to go along with it. My mind felt like it was working in overdrive and I wanted to talk to anyone about anything I possibly could…” • “At about 1 hour and 10 minutes in I got the strongest urge to redose I have ever felt from a drug, including cocaine.” Physical Properties • White to Light Brown • Hydrophilic • Crumbly powder • Slight odor Michigan; How it Began • First call December 18, 2010 • First Death February 3 2011 • February 2-7 10 cases • Reported – Bay City – Iron Wood – Mt. Clemons PCC & Health Department Need PCC MDCH 24/7 Call Center Yes No Able to give medical advice Yes No Real-time reporting Yes Yes Able to mandate reporting No Yes Able to take legal action No Yes Able to create EPI-X alerts* Yes Yes Able to create HAN* No Yes Able to submit MMWR* No Yes Participates in
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn Et Al
    US 2003.0068365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn et al. (43) Pub. Date: Apr. 10, 2003 (54) COMPOSITIONS AND METHODS FOR Related U.S. Application Data ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME BEADS (60) Provisional application No. 60/327,643, filed on Oct. 5, 2001. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); Tanusin Ploysangam, Bangkok (TH); Publication Classification Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok (51) Int. Cl." .......................... A61K 9/127; A61K 35/78 (TH); Nardo Zaias, Miami Beach, FL (52) U.S. Cl. ............................................ 424/450; 424/725 (US) (57) ABSTRACT Correspondence Address: Law Office of Eric G. Masamori Compositions and methods for administration of active 6520 Ridgewood Drive agents encapsulated within liposome beads to enable a wider Castro Valley, CA 94.552 (US) range of delivery vehicles, to provide longer product shelf life, to allow multiple active agents within the composition, (21) Appl. No.: 10/264,205 to allow the controlled use of the active agents, to provide protected and designable release features and to provide (22) Filed: Oct. 3, 2002 Visual inspection for damage and inconsistency. US 2003/0068365A1 Apr. 10, 2003 COMPOSITIONS AND METHODS FOR toxic degradation of the products, leakage of the drug from ADMINISTRATION OF ACTIVE AGENTS USING the liposome and the modifications of the Size and morphol LPOSOME BEADS ogy of the phospholipid liposome vesicles through aggre gation and fusion. Liposome vesicles are known to be CROSS REFERENCE TO OTHER thermodynamically relatively unstable at room temperature APPLICATIONS and can Spontaneously fuse into larger, leSS Stable altered liposome forms.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Synthesis and Positive Inotropic Activity of [1,2,4]Triazolo[4,3-A] Quinoxaline Derivatives Bearing Substituted Benzylpiperazine and Benzoylpiperazine Moieties
    molecules Article Synthesis and Positive Inotropic Activity of [1,2,4]Triazolo[4,3-a] Quinoxaline Derivatives Bearing Substituted Benzylpiperazine and Benzoylpiperazine Moieties Xue-Kun Liu 1,†, Long-Xu Ma 2,†, Zhi-Yu Wei 2, Xun Cui 3, Shi Zhan 4, Xiu-Mei Yin 2,* and Hu-Ri Piao 2,* 1 Tonghua Normal University , College of Pharmaceutical and Food Science, Tonghua 134002, China; [email protected] 2 Key Laboratory of Natural Resources of Changbai Mountain & Functional Molecules, Ministry of Education, College of Pharmacy, Yanbian University, Yanji 133000, China; [email protected] (L.-X.M.); [email protected] (Z.-Y.W.) 3 College of Medicine, Yanbian University, Yanji 133000, China; [email protected] 4 State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, College of Chemistry, Jilin University, Changchun 130000, China; [email protected] * Correspondences: [email protected] (X.-M.Y.); [email protected] (H.-R.P.); Tel.: +86-433-243-6019 (X.-M.Y.); +86-433-243-5003 (H.-R.P.); Fax: +86-433-243-5026 (X.-M.Y.); +86-433-243-5026 (H.-R.P.) † These authors contributed equally to this work. Academic Editor: Derek J. McPhee Received: 15 January 2017; Accepted: 8 February 2017; Published: 11 February 2017 Abstract: In an attempt to search for more potent positive inotropic agents, two series of [1,2,4]triazolo[4,3-a] quinoxaline derivatives bearing substituted benzylpiperazine and benzoylpiperazine moieties were synthesized and their positive inotropic activities evaluated by measuring left atrial stroke volume in isolated rabbit heart preparations. Several compounds showed favorable activities compared with the standard drug, milrinone.
    [Show full text]